Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이화정 | * |
dc.date.accessioned | 2016-08-28T12:08:54Z | - |
dc.date.available | 2016-08-28T12:08:54Z | - |
dc.date.issued | 2012 | * |
dc.identifier.issn | 0928-0987 | * |
dc.identifier.other | OAK-8448 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/222344 | - |
dc.description.abstract | The aims of the present study were to investigate the effects of silymarin, an inhibitor of the P-glycoprotein efflux pump, on oral bioavailability of paclitaxel in rats, and to compare pharmacokinetic parameters of paclitaxel between a commercial formulation of paclitaxel (Taxol®) and a paclitaxel microemulsion. Oral bioavailability of paclitaxel in a Taxol® formulation was enhanced in the combination with silymarin (10 and 20 mg/kg). In particular, the mean maximum plasma concentration (C max) and the mean area under the plasma concentration-time curve (AUC 0-t) of paclitaxel in the Taxol® formulation were significantly increased 3-fold and 5-fold compared with control, respectively, following oral co-administration with 10 mg/kg of silymarin (p < 0.01). When the paclitaxel microemulsion was co-administered with silymarin (20 mg/kg) orally, it caused a maximum increase in the absolute bioavailability of paclitaxel (19%). In addition, the relative bioavailability of the paclitaxel microemulsion was 184% as compared to Taxol® after oral dosing, whereas the mean time required to reach C max (T max) of paclitaxel was decreased in the microemulsion formulation compared with Taxol®, suggesting faster absorption. Based on these results, we conclude that oral bioavailability of paclitaxel is significantly improved by co-administration with silymarin, an inhibitor of the P-gp efflux pump and by microemulsion formulation. © 2011 Elsevier B.V. All rights reserved. | * |
dc.language | English | * |
dc.title | Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 45 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 296 | * |
dc.relation.lastpage | 301 | * |
dc.relation.journaltitle | European Journal of Pharmaceutical Sciences | * |
dc.identifier.doi | 10.1016/j.ejps.2011.11.021 | * |
dc.identifier.wosid | WOS:000300130200006 | * |
dc.identifier.scopusid | 2-s2.0-84855800458 | * |
dc.author.google | Park J.H. | * |
dc.author.google | Hur H.J. | * |
dc.author.google | Woo J.S. | * |
dc.author.google | Lee H.J. | * |
dc.contributor.scopusid | 이화정(57102029300) | * |
dc.date.modifydate | 20240118154655 | * |